FDA's Document Dump: Guidance Release Skyrocketed In Advance Of Trump
Uncertainty about US FDA's direction under the new president may have spurred staff to ensure views on several issues released before administration changed.
You may also be interested in...
Incoming president will not hold over any FDA political appointees from the Obama administration, but what exactly his stamp on the agency will be remains unclear.
Two draft guidance documents would allow a broader range of communications with payers and others about information not included on device labeling, or concerning products without FDA approval.
Draft guidance provides clarity on what health care economic information firms can provide to payors, formulary committees and similar entities.